#BEGIN_DRUGCARD DB01117

# AHFS_Codes:
08:30.92

# ATC_Codes:
P01AX06

# Absorption:
The bioavailability of atovaquone is low and variable and is highly dependent on formulation and diet. Bioavailability of the suspension increases two-fold when administered with meals. When administered with food, bioavailability is approximately 47%. Without food, the bioavailability is 23%.

# Biotransformation:
Some evidence suggests limited metabolism (although no metabolites have been identified).

# Brand_Mixtures:
Malarone (Atovaquone + Proguanil Hydrochloride)
Malarone Pediatric (Atovaquone + Proguanil Hydrochloride)

# Brand_Names:
Malarone Pediatric

# CAS_Registry_Number:
95233-18-4

# ChEBI_ID:
575568

# Chemical_Formula:
C22H19ClO3

# Chemical_IUPAC_Name:
2-hydroxy-3-[(1r,4r)-4-(4-chlorophenyl)cyclohexyl]-1,4-dihydronaphthalene-1,4-dione

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2217422

# Description:
A hydroxynaphthoquinone that has antimicrobial activity and is being used in antimalarial protocols. [PubChem]

# Dosage_Forms:
Suspension	Oral

# Drug_Category:
Anti-Infective Agents
Antifungal Agents
Antimalarials
Antiprotozoal Agents
Enzyme Inhibitors

# Drug_Interactions:
Rifabutin	Rifabutin decreases the effect of atovaquone
Rifampin	Rifampin may decrease the effect of atovaquone.
Tetracycline	Tetracycline may decrease the effect of atovaquone.
Zidovudine	Atovaquone increases the effect and toxicity of zidovudine

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
5.8

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Practically insoluble

# Food_Interactions:
Fatty foods increase absorption.
Take with food, bioavailability is increased 2 to 3 fold.

# GenBank_ID:
Not Available

# Generic_Name:
Atovaquone

# HET_ID:
Not Available

# Half_Life:
2.2 to 3.2 days

# InChI_Identifier:
InChI=1S/C22H19ClO3/c23-16-11-9-14(10-12-16)13-5-7-15(8-6-13)19-20(24)17-3-1-2-4-18(17)21(25)22(19)26/h1-4,9-13,15,26H,5-8H2/t13-,15-

# InChI_Key:
InChIKey=KUCQYCKVKVOKAY-CTYIDZIISA-N

# Indication:
For the treatment or prevention of <i>Pneumocystis carinii</i> pneumonia in patients who are intolerant to trimethoprim-sulfamethoxazole (TMP-SMX). Also indicated for the acute oral treatment of mild to moderate PCP in patients who are intolerant to TMP-SMX.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D00236

# LIMS_Drug_ID:
1117

# Mechanism_Of_Action:
Atovaquone is a hydroxy- 1, 4- naphthoquinone, an analog of ubiquinone, with antipneumocystis activity. The mechanism of action against <i>Pneumocystis carinii</i> has not been fully elucidated. In Plasmodium species, the site of action appears to be the cytochrome bc1 complex (Complex III). Several metabolic enzymes are linked to the mitochondrial electron transport chain via ubiquinone. Inhibition of electron transport by atovaquone will result in indirect inhibition of these enzymes. The ultimate metabolic effects of such blockade may include inhibition of nucleic acid and ATP synthesis. Atovaquone also has been shown to have good <i>in vitro</i> activity against <i>Toxoplasma gondii</i>.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
366.837

# Molecular_Weight_Mono:
366.102272181

# Organisms_Affected:
Plasmodium

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA448502

# Pharmacology:
Atovaquone is a highly lipophilic drug that closely resembles the structure ubiquinone. Its inhibitory effect being comparable to ubiquinone, in sensitive parasites atovaquone can act by selectively affecting mitochondrial electron transport and parallel processes such as ATP and pyrimidine biosynthesis. For illustration, cytochrome bc1 complex (complex III) seems to serve as a highly discriminating molecular target for atovaquone in Plasmodia
atovaquone has the advantage of not causing myelosuppression, which is an important issue in patients who have undergone bone marrow transplantation.

# Predicted_LogP_Hydrophobicity:
4.74

# Predicted_LogS:
-5.7

# Predicted_Water_Solubility:
7.96e-04 g/l

# Primary_Accession_No:
DB01117

# Protein_Binding:
Atovaquone is extensively bound to plasma proteins (99.9%) over the concentration range of 1 to 90 &micro;g/mL.

# PubChem_Compound_ID:
74989

# PubChem_Substance_ID:
46507298

# RxList_Link:
http://www.rxlist.com/cgi/generic/atovaqu.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00805

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OC1=C([C@H]2CC[C@@H](CC2)C2=CC=C(Cl)C=C2)C(=O)C2=CC=CC=C2C1=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
The median lethal dose is higher than the maximum oral dose tested in mice and rats (1825 mg/kg per day). Overdoses up to 31,500 mg of atovaquone have been reported. In one such patient who also took an unspecified dose of dapsone, methemoglobinemia occurred. Rash has also been reported after overdose.

# Update_Date:
2013-02-08 16:19:55 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Atovaquone

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP2C9

# Phase_1_Metabolizing_Enzyme_1_ID:
4757

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 2C9

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 2C9
MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKV
YGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFM
KSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYID
LLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNFK
KSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVP
PFYQLCFIPV

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P11712

# Drug_Target_1_Cellular_Location:
Mitochondrion inner membrane

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10447880	Srivastava IK, Morrisey JM, Darrouzet E, Daldal F, Vaidya AB: Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites. Mol Microbiol. 1999 Aug;33(4):704-11.
10593174	Syafruddin D, Siregar JE, Marzuki S: Mutations in the cytochrome b gene of Plasmodium berghei conferring resistance to atovaquone. Mol Biochem Parasitol. 1999 Nov 30;104(2):185-94.
10681344	Cushion MT, Collins M, Hazra B, Kaneshiro ES: Effects of atovaquone and diospyrin-based drugs on the cellular ATP of Pneumocystis carinii f. sp. carinii. Antimicrob Agents Chemother. 2000 Mar;44(3):713-9.
10802314	McFadden DC, Tomavo S, Berry EA, Boothroyd JC: Characterization of cytochrome b from Toxoplasma gondii and Q(o) domain mutations as a mechanism of atovaquone-resistance. Mol Biochem Parasitol. 2000 Apr 30;108(1):1-12.
11181161	Kazanjian P, Armstrong W, Hossler PA, Lee CH, Huang L, Beard CB, Carter J, Crane L, Duchin J, Burman W, Richardson J, Meshnick SR: Pneumocystis carinii cytochrome b mutations are associated with atovaquone exposure in patients with AIDS. J Infect Dis. 2001 Mar 1;183(5):819-22. Epub 2001 Feb 1.
11906048	Meshnick SR, Berry EA, Nett J, Kazanjian P, Trumpower B: The interaction of atovaquone with the P. carinii cytochrome bc1 complex. J Eukaryot Microbiol. 2001;Suppl:169S-171S.
11991686	Kaneshiro ES: Are cytochrome b gene mutations the only cause of atovaquone resistance in Pneumocystis? Drug Resist Updat. 2001 Oct;4(5):322-9.
12791689	Kessl JJ, Lange BB, Merbitz-Zahradnik T, Zwicker K, Hill P, Meunier B, Palsdottir H, Hunte C, Meshnick S, Trumpower BL: Molecular basis for atovaquone binding to the cytochrome bc1 complex. J Biol Chem. 2003 Aug 15;278(33):31312-8. Epub 2003 Jun 5.
15718226	Kessl JJ, Ha KH, Merritt AK, Lange BB, Hill P, Meunier B, Meshnick SR, Trumpower BL: Cytochrome b mutations that modify the ubiquinol-binding pocket of the cytochrome bc1 complex and confer anti-malarial drug resistance in Saccharomyces cerevisiae. J Biol Chem. 2005 Apr 29;280(17):17142-8. Epub 2005 Feb 17.
18082162	Winter RW, Kelly JX, Smilkstein MJ, Dodean R, Hinrichs D, Riscoe MK: Antimalarial quinolones: synthesis, potency, and mechanistic studies. Exp Parasitol. 2008 Apr;118(4):487-97. Epub 2007 Nov 7.

# Drug_Target_1_Essentiality:
Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
M99416

# Drug_Target_1_GenBank_ID_Protein:
2978420

# Drug_Target_1_GeneCard_ID:
MT-CYB

# Drug_Target_1_Gene_Name:
MT-CYB

# Drug_Target_1_Gene_Sequence:
>1131 bp
ATGAACTTTTACTCTATTAATTTAGTTAAAGCACACTTAATAAATTACCCATGTCCATTG
AACATAAACTTTTTATGGAATTACGGATTCCTTTTAGGAATAATATTTTTTATTCAAATT
ATAACAGGTGTATTTTTAGCAAGTCGATATACACCAGATGTTTCATATGCATATTATAGT
ATACAACACATTTTAAGAGAATTATGGAGTGGATGGTGTTTTAGATACATGCACGCAACA
GGTGCTTCTCTTGTATTTTTATTAACATATCTTCATATTTTAAGAGGATTAAATTACTCA
TATATGTATTTACCATTATCATGGATATCTGGATTGATTTTATTTATGATATTTATTGTA
ACTGCTTTCGTTGGTTATGTCTTACCATGGGGTCAAATGAGTTATTGGGGTGCAACTGTA
ATTACTAACTTGTTATCCTCTATTCCAGTAGCAGTAATTTGGATATGTGGAGGATATACT
GTGAGTGATCCTACAATAAAACGATTTTTTGTACTACATTTTATCTTACCATTTATTGGA
TTATGTATTGTATTTATACATATATTTTTCTTACATTTACATGGTAGCACAAATCCTTTA
GGGTATGATACAGCATTAAAAATACCCTTTTATCCAAATCTATTAAGTCTTGATGTTAAA
GGATTTAATAATGTTATAATTTTATTTCTAATACAAAGTTTATTTGGAATTATACCTTTA
TCACATCCTGATAATGCTATCGTAGTAAATACATATGTTACTCCATCTCAAATTGTACCT
GAATGGTACTTTCTACCATTTTATGCAATGTTAAAAACTGTTCCAAGTAAACCAGCTGGT
TTAGTAATTGTATTATTATCATTACAATTATTATTCTTATTAGCAGAACAAAGAAGTTTA
ACAACTATAATTCAATTTAAAATGATTTTTGGTGCTAGAGATTATTCTGTTCCTATTATA
TGGTTTATGTGTGCATTCTATGCTTTATTATGGATTGGATGTCAATTACCACAAGATATA
TTCATTTTATATGGTCGATTATTTATTGTATTATTTTTCTGTAGTGGTTTATTTGTACTT
GTTCATTATAGACGAACACATTATGATTACAGCTCCCAAGCAAACATATAA

# Drug_Target_1_General_Function:
Energy production and conversion

# Drug_Target_1_General_References:
1542578	Feagin JE, Werner E, Gardner MJ, Williamson DH, Wilson RJ: Homologies between the contiguous and fragmented rRNAs of the two Plasmodium falciparum extrachromosomal DNAs are limited to core sequences. Nucleic Acids Res. 1992 Feb 25;20(4):879-87.
3054536	Suplick K, Akella R, Saul A, Vaidya AB: Molecular cloning and partial sequence of a 5.8 kilobase pair repetitive DNA from Plasmodium falciparum. Mol Biochem Parasitol. 1988 Sep;30(3):289-90.
8459834	Vaidya AB, Lashgari MS, Pologe LG, Morrisey J: Structural features of Plasmodium cytochrome b that may underlie susceptibility to 8-aminoquinolines and hydroxynaphthoquinones. Mol Biochem Parasitol. 1993 Mar;58(1):33-42.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
6937

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
43376.2

# Drug_Target_1_Name:
Cytochrome b

# Drug_Target_1_Number_of_Residues:
376

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00032	Cytochrom_B_C
PF00033	Cytochrom_B_N

# Drug_Target_1_Protein_Sequence:
>Cytochrome b
MNFYSINLVKAHLINYPCPLNINFLWNYGFLLGIIFFIQIITGVFLASRYTPDVSYAYYS
IQHILRELWSGWCFRYMHATGASLVFLLTYLHILRGLNYSYMYLPLSWISGLILFMIFIV
TAFVGYVLPWGQMSYWGATVITNLLSSIPVAVIWICGGYTVSDPTIKRFFVLHFILPFIG
LCIVFIHIFFLHLHGSTNPLGYDTALKIPFYPNLLSLDVKGFNNVIILFLIQSLFGIIPL
SHPDNAIVVNTYVTPSQIVPEWYFLPFYAMLKTVPSKPAGLVIVLLSLQLLFLLAEQRSL
TTIIQFKMIFGARDYSVPIIWFMCAFYALLWIGCQLPQDIFILYGRLFIVLFFCSGLFVL
VHYRRTHYDYSSQANI

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Component of the ubiquinol-cytochrome c reductase complex (complex III or cytochrome b-c1 complex), which is a respiratory chain that generates an electrochemical potential coupled to ATP synthesis (By similarity)

# Drug_Target_1_SwissProt_ID:
Q02768

# Drug_Target_1_SwissProt_Name:
CYB_PLAFA

# Drug_Target_1_Synonyms:
Complex III subunit 3
Complex III subunit III
Cytochrome b-c1 complex subunit 3
Ubiquinol-cytochrome-c reductase complex cytochrome b subunit

# Drug_Target_1_Theoretical_pI:
8.72

# Drug_Target_1_Transmembrane_Regions:
28-48
77-97
108-128
136-156
169-189
221-241
247-267
274-294
317-337
340-360

# Drug_Target_2_Cellular_Location:
Mitochondrion
mitochondrial inner membrane (Probable)

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10681344	Cushion MT, Collins M, Hazra B, Kaneshiro ES: Effects of atovaquone and diospyrin-based drugs on the cellular ATP of Pneumocystis carinii f. sp. carinii. Antimicrob Agents Chemother. 2000 Mar;44(3):713-9.
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
7726490	Ittarat I, Asawamahasakda W, Bartlett MS, Smith JW, Meshnick SR: Effects of atovaquone and other inhibitors on Pneumocystis carinii dihydroorotate dehydrogenase. Antimicrob Agents Chemother. 1995 Feb;39(2):325-8.
7909690	Seymour KK, Lyons SD, Phillips L, Rieckmann KH, Christopherson RI: Cytotoxic effects of inhibitors of de novo pyrimidine biosynthesis upon Plasmodium falciparum. Biochemistry. 1994 May 3;33(17):5268-74.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
CR382398

# Drug_Target_2_GenBank_ID_Protein:
46362265

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
PFF0160c

# Drug_Target_2_Gene_Sequence:
>1710 bp
ATGATCTCTAAATTGAAACCTCAATTTATGTTTTTACCAAAGAAACATATTTTAAGTTAT
TGTAGAAAGGATGTTTTAAATTTGTTTGAACAGAAGTTTTATTATACTAGCAAACGGAAA
GAAAGTAATAATATGAAGAATGAATCTTTATTAAGATTAATTAATTATAATAGATATTAT
AATAAGATAGATTCTAATAATTATTATAATGGTGGAAAAATATTAAGTAATGATAGGCAA
TATATATATTCACCATTATGTGAATATAAAAAGAAAATAAATGATATATCATCATATGTA
TCTGTACCTTTTAAGATTAATATAAGAAATTTAGGTACTTCCAATTTTGTAAATAATAAG
AAGGATGTACTTGATAATGATTATATTTATGAAAATATTAAAAAAGAAAAATCTAAGCAT
AAAAAAATAATATTTTTATTATTTGTTTCATTATTTGGATTATATGGTTTTTTTGAATCT
TATAATCCTGAATTTTTTTTATATGATATATTTTTAAAATTCTGTTTAAAATATATTGAT
GGTGAAATATGTCATGACCTTTTTTTATTACTAGGAAAATATAATATATTACCATATGAT
ACTAGTAATGATAGTATATATGCATGTACAAATATTAAACATCTTGATTTTATAAATCCA
TTCGGTGTTGCTGCAGGATTTGATAAAAACGGTGTATGTATAGATAGCATATTAAAATTA
GGGTTTTCGTTTATCGAAATTGGTACCATAACCCCAAGGGGCCAAACGGGTAATGCAAAA
CCACGTATTTTTAGAGACGTTGAATCTAGAAGTATTATAAATTCATGTGGCTTTAATAAT
ATGGGTTGTGACAAAGTTACAGAAAATTTAATACTTTTTCGTAAAAGACAAGAAGAAGAT
AAATTGTTAAGTAAACATATTGTAGGTGTCAGTATAGGTAAGAATAAAGATACTGTTAAT
ATTGTAGATGATCTAAAATATTGTATTAATAAAATAGGAAGATACGCTGATTATATAGCT
ATTAATGTAAGCTCCCCTAATACACCTGGGTTAAGAGATAATCAAGAAGCTGGGAAGTTA
AAAAATATAATTTTAAGTGTAAAAGAAGAAATAGATAATTTAGAAAAGAATAATATTATG
AATGATGAAAGTACTTATAATGAAGATAATAAAATAGTAGAAAAAAAAAATAATTTTAAT
AAAAATAATAGTCACATGATGAAAGATGCTAAGGATAACTTCTTATGGTTTAATACAACA
AAAAAGAAGCCCTTGGTTTTTGTTAAGTTAGCTCCAGATCTTAATCAAGAACAGAAAAAA
GAAATTGCTGATGTATTACTTGAAACTAATATAGATGGTATGATTATTTCTAATACTACG
ACACAAATAAATGACATAAAAAGTTTTGAAAATAAAAAAGGAGGTGTTAGCGGAGCAAAA
CTAAAAGATATATCTACAAAATTTATATGTGAAATGTATAATTATACAAATAAACAAATA
CCCATTATTGCATCAGGAGGGATATTTAGTGGATTGGATGCTTTAGAAAAAATTGAAGCA
GGTGCTTCAGTTTGTCAATTATATTCTTGTTTGGTTTTTAATGGTATGAAATCAGCTGTA
CAAATAAAAAGAGAATTGAATCACTTGCTATATCAAAGAGGATATTACAATTTAAAGGAG
GCCATTGGCCGAAAGCATAGCAAAAGTTAA

# Drug_Target_2_General_Function:
Nucleotide transport and metabolism

# Drug_Target_2_General_References:
12368867	Hall N, Pain A, Berriman M, Churcher C, Harris B, Harris D, Mungall K, Bowman S, Atkin R, Baker S, Barron A, Brooks K, Buckee CO, Burrows C, Cherevach I, Chillingworth C, Chillingworth T, Christodoulou Z, Clark L, Clark R, Corton C, Cronin A, Davies R, Davis P, Dear P, Dearden F, Doggett J, Feltwell T, Goble A, Goodhead I, Gwilliam R, Hamlin N, Hance Z, Harper D, Hauser H, Hornsby T, Holroyd S, Horrocks P, Humphray S, Jagels K, James KD, Johnson D, Kerhornou A, Knights A, Konfortov B, Kyes S, Larke N, Lawson D, Lennard N, Line A, Maddison M, McLean J, Mooney P, Moule S, Murphy L, Oliver K, Ormond D, Price C, Quail MA, Rabbinowitsch E, Rajandream MA, Rutter S, Rutherford KM, Sanders M, Simmonds M, Seeger K, Sharp S, Smith R, Squares R, Squares S, Stevens K, Taylor K, Tivey A, Unwin L, Whitehead S, Woodward J, Sulston JE, Craig A, Newbold C, Barrell BG: Sequence of Plasmodium falciparum chromosomes 1, 3-9 and 13. Nature. 2002 Oct 3;419(6906):527-31.
8232427	LeBlanc SB, Wilson CM: The dihydroorotate dehydrogenase gene homologue of Plasmodium falciparum. Mol Biochem Parasitol. 1993 Aug;60(2):349-51.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
674

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
65559

# Drug_Target_2_Name:
Dihydroorotate dehydrogenase homolog, mitochondrial

# Drug_Target_2_Number_of_Residues:
569

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF01180	DHO_dh

# Drug_Target_2_Protein_Sequence:
>Dihydroorotate dehydrogenase homolog, mitochondrial precursor
MISKLKPQFMFLPKKHILSYCRKDVLNLFEQKFYYTSKRKESNNMKNESLLRLINYNRYY
NKIDSNNYYNGGKILSNDRQYIYSPLCEYKKKINDISSYVSVPFKINIRNLGTSNFVNNK
KDVLDNDYIYENIKKEKSKHKKIIFLLFVSLFGLYGFFESYNPEFFLYDIFLKFCLKYID
GEICHDLFLLLGKYNILPYDTSNDSIYACTNIKHLDFINPFGVAAGFDKNGVCIDSILKL
GFSFIEIGTITPRGQTGNAKPRIFRDVESRSIINSCGFNNMGCDKVTENLILFRKRQEED
KLLSKHIVGVSIGKNKDTVNIVDDLKYCINKIGRYADYIAINVSSPNTPGLRDNQEAGKL
KNIILSVKEEIDNLEKNNIMNDESTYNEDNKIVEKKNNFNKNNSHMMKDAKDNFLWFNTT
KKKPLVFVKLAPDLNQEQKKEIADVLLETNIDGMIISNTTTQINDIKSFENKKGGVSGAK
LKDISTKFICEMYNYTNKQIPIIASGGIFSGLDALEKIEAGASVCQLYSCLVFNGMKSAV
QIKRELNHLLYQRGYYNLKEAIGRKHSKS

# Drug_Target_2_Reaction:
(S)-dihydroorotate + O2 = orotate + H2O2

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Not Available

# Drug_Target_2_SwissProt_ID:
Q08210

# Drug_Target_2_SwissProt_Name:
PYRD_PLAF7

# Drug_Target_2_Synonyms:
DHOdehase
Dihydroorotate dehydrogenase homolog, mitochondrial precursor
Dihydroorotate oxidase
EC 1.3.3.1

# Drug_Target_2_Theoretical_pI:
9.44

# Drug_Target_2_Transmembrane_Regions:
143-162

# Drug_Target_3_Cellular_Location:
Mitochondrion
mitochondrial inner membrane

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
10658902	Knecht W, Henseling J, Loffler M: Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact. 2000 Jan 3;124(1):61-76.
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
15044733	Hansen M, Le Nours J, Johansson E, Antal T, Ullrich A, Loffler M, Larsen S: Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domain. Protein Sci. 2004 Apr;13(4):1031-42.
7726490	Ittarat I, Asawamahasakda W, Bartlett MS, Smith JW, Meshnick SR: Effects of atovaquone and other inhibitors on Pneumocystis carinii dihydroorotate dehydrogenase. Antimicrob Agents Chemother. 1995 Feb;39(2):325-8.
7909690	Seymour KK, Lyons SD, Phillips L, Rieckmann KH, Christopherson RI: Cytotoxic effects of inhibitors of de novo pyrimidine biosynthesis upon Plasmodium falciparum. Biochemistry. 1994 May 3;33(17):5268-74.
9425362	Seymour KK, Yeo AE, Rieckmann KH, Christopherson RI: dCTP levels are maintained in Plasmodium falciparum subjected to pyrimidine deficiency or excess. Ann Trop Med Parasitol. 1997 Sep;91(6):603-9.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
DHODH

# Drug_Target_3_GenBank_ID_Gene:
M94065

# Drug_Target_3_GenBank_ID_Protein:
555594

# Drug_Target_3_GeneCard_ID:
DHODH

# Drug_Target_3_Gene_Name:
DHODH

# Drug_Target_3_Gene_Sequence:
>1191 bp
AAATTACCGTGGAGACACCTGCAAAAGCGGGCCCAGGATGCTGTGATCATCCTGGGGGGA
GGAGGACTTCTCTTCGCCTCCTACCTGATGGCCACGGGAGATGAGCGTTTCTATGCTGAA
CACCTGATGCCGACTCTGCAGGGGCTGCTGGACCCGGAGTCAGCCCACAGACTGGCTGTT
CGCTTCACCTCCCTGGGGCTCCTTCCACGGGCCAGATTTCAAGACTCTGACATGCTGGAA
GTGAGAGTTCTGGGCCATAAATTCCGAAATCCAGTAGGAATTGCTGCAGGATTTGACAAG
CATGGGGAAGCCGTGGACGGACTTTATAAGATGGGCTTTGGTTTTGTTGAGATAGGAAGT
GTGACTCCAAAACCTCAGGAAGGAAACCCTAGACCCAGAGTCTTCCGCCTCCCTGAGGAC
CAAGCTGTCATTAACAGGTATGGATTTAACAGTCACGGGCTTTCAGTGGTGGAACACAGG
TTACGGGCCAGACAGCAGAAGCAGGCCAAGCTCACAGAAGATGGACTGCCTCTGGGGGTC
AACTTGGGGAAGAACAAGACCTCAGTGGACGCCGCGGAGGACTACGCAGAAGGGGTGCGC
GTACTGGGCCCCCTGGCCGACTACCTGGTGGTGAATGTGTCCAGCCCCAACACTGCCGGG
CTGCGGAGCCTTCAGGGAAAGGCCGAGCTGCGCCGCCTGCTGACCAAGGTGCTGCAGGAG
AGGGATGGCTTGCGGAGAGTGCACAGGCCGGCAGTCCTGGTGAAGATCGCTCCTGACCTC
ACCAGCCAGGATAAGGAGGACATTGCCAGTGTGGTCAAAGAGTTGGGCATCGATGGGCTG
ATTGTTACGAACACCACCGTGAGTCGCCCTGCGGGCCTCCAGGGTGCCCTGCGCTCTGAA
ACAGGAGGGCTGAGTGGGAAGCCCCTCCGGGATTTATCAACTCAAACCATTCGGGAGATG
TATGCACTCACCCAAGGCCGAGTTCCCATAATTGGGGTTGGTGGTGTGAGCAGCGGGCAG
GACGCGCTGGAGAAGATCCGGGCAGGGGCCTCCCTGGTGCAGCTGTACACGGCCCTCACC
TTCTGGGGGCCACCCGTTGTGGGCAAAGTCAAGCGGGAACTGGAGGCCCTTCTGAAAGAG
CAGGGCTTTGGCGGAGTCACAGATGCCATTGGAGCAGATCATCGGAGGTGA

# Drug_Target_3_General_Function:
Nucleotide transport and metabolism

# Drug_Target_3_General_References:
1446837	Minet M, Dufour ME, Lacroute F: Cloning and sequencing of a human cDNA coding for dihydroorotate dehydrogenase by complementation of the corresponding yeast mutant. Gene. 1992 Nov 16;121(2):393-6.

# Drug_Target_3_HGNC_ID:
HGNC:2867

# Drug_Target_3_HPRD_ID:
00521

# Drug_Target_3_ID:
424

# Drug_Target_3_Locus:
16q22

# Drug_Target_3_Molecular_Weight:
42868

# Drug_Target_3_Name:
Dihydroorotate dehydrogenase, mitochondrial

# Drug_Target_3_Number_of_Residues:
395

# Drug_Target_3_PDB_ID:
1D3H

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF01180	DHO_dh

# Drug_Target_3_Protein_Sequence:
>Dihydroorotate dehydrogenase, mitochondrial precursor
MAWRHLKKRAQDAVIILGGGGLLFASYLMATGDERFYAEHLMPTLQGLLDPESAHRLAVR
FTSLGLLPRARFQDSDMLEVRVLGHKFRNPVGIAAGFDKHGEAVDGLYKMGFGFVEIGSV
TPKPQEGNPRPRVFRLPEDQAVINRYGFNSHGLSVVEHRLRARQQKQAKLTEDGLPLGVN
LGKNKTSVDAAEDYAEGVRVLGPLADYLVVNVSSPNTAGLRSLQGKAELRRLLTKVLQER
DGLRRVHRPAVLVKIAPDLTSQDKEDIASVVKELGIDGLIVTNTTVSRPAGLQGALRSET
GGLSGKPLRDLSTQTIREMYALTQGRVPIIGVGGVSSGQDALEKIRAGASLVQLYTALTF
WGPPVVGKVKRELEALLKEQGFGGVTDAIGADHRR

# Drug_Target_3_Reaction:
(S)-dihydroorotate + O2 = orotate + H2O2

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Not Available

# Drug_Target_3_SwissProt_ID:
Q02127

# Drug_Target_3_SwissProt_Name:
PYRD_HUMAN

# Drug_Target_3_Synonyms:
DHOdehase
Dihydroorotate dehydrogenase, mitochondrial precursor
Dihydroorotate oxidase
EC 1.3.3.1

# Drug_Target_3_Theoretical_pI:
10.23

# Drug_Target_3_Transmembrane_Regions:
13-32

#END_DRUGCARD DB01117
